<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-title>Diabetologia</journal-title><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18504547</article-id><article-id pub-id-type="publisher-id">1031</article-id><article-id pub-id-type="doi">10.1007/s00125-008-1031-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Moderate alcohol consumption increases insulin sensitivity and <italic>ADIPOQ</italic> expression in postmenopausal women: a randomised, crossover trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Joosten</surname><given-names>M. M.</given-names></name><address><email>michel.joosten@wur.nl</email><email>michel.joosten@tno.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beulens</surname><given-names>J. W. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kersten</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>H. F. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Business Unit Biosciences, TNO Quality of Life, P. O. Box 360, 3700 AJ Zeist, the Netherlands </aff><aff id="Aff2"><label>2</label>Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>5</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2008</year></pub-date><volume>51</volume><issue>8</issue><fpage>1375</fpage><lpage>1381</lpage><history><date date-type="received"><day>7</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>7</day><month>4</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2008</copyright-statement></permissions><abstract><sec><title>Aims/hypothesis</title><p>To determine whether 6 weeks of daily, moderate alcohol consumption increases expression of the gene encoding adiponectin (<italic>ADIPOQ</italic>) and plasma levels of the protein, and improves insulin sensitivity in postmenopausal women.</p></sec><sec><title>Methods</title><p>In a randomised, open-label, crossover trial conducted in the Netherlands, 36 apparently healthy postmenopausal women who were habitual alcohol consumers, received 250&#x000a0;ml white wine (&#x0223c;25&#x000a0;g alcohol/day) or 250&#x000a0;ml of white grape juice (control) daily during dinner for 6&#x000a0;weeks. Randomisation to treatment allocation occurred according to BMI. Insulin sensitivity and <italic>ADIPOQ</italic> mRNA and plasma adiponectin levels were measured at the end of both periods. Insulin sensitivity was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR). Levels of <italic>ADIPOQ</italic> mRNA in subcutaneous adipose tissue were determined by RT-PCR.</p></sec><sec><title>Results</title><p>All subjects completed the study. Six weeks of white wine consumption reduced fasting insulin (mean&#x02009;&#x000b1;&#x02009;SEM 40.0&#x02009;&#x000b1;&#x02009;3.4 vs 46.5&#x02009;&#x000b1;&#x02009;3.4&#x000a0;pmol/l; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and HOMA-IR (1.42&#x02009;&#x000b1;&#x02009;0.13 vs 1.64&#x02009;&#x000b1;&#x02009;0.13; <italic>p</italic>&#x02009;=&#x02009;0.02) compared with 6 weeks of grape juice consumption. <italic>ADIPOQ</italic> mRNA levels (1.09&#x02009;&#x000b1;&#x02009;0.15 vs 0.98&#x02009;&#x000b1;&#x02009;0.15; <italic>p</italic>&#x02009;=&#x02009;0.04) and plasma levels of total (13.1&#x02009;&#x000b1;&#x02009;0.8 vs 12.0&#x02009;&#x000b1;&#x02009;0.8&#x000a0;&#x003bc;g/ml; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and high molecular weight (HMW) adiponectin (9.9&#x02009;&#x000b1;&#x02009;1.2 vs 8.8&#x02009;&#x000b1;&#x02009;1.2&#x000a0;&#x003bc;g/ml; <italic>p</italic>&#x02009;=&#x02009;0.02) significantly increased after alcohol compared with juice consumption. Changes in <italic>ADIPOQ</italic> mRNA levels correlated with changes in plasma levels of total adiponectin (<italic>&#x003c1;</italic>&#x02009;=&#x02009;0.46; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). Both fasting triacylglycerol (8.2%; <italic>p</italic>&#x02009;=&#x02009;0.04) and LDL-cholesterol levels (7.8%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) decreased, whereas HDL-cholesterol increased (7.0%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) after prolonged moderate alcohol intake. No notable adverse effects were reported.</p></sec><sec><title>Conclusions/interpretation</title><p>Moderate alcohol consumption for 6&#x000a0;weeks improves insulin sensitivity, adiponectin levels and lipid profile in postmenopausal women. Furthermore, these data suggest a transcriptional mechanism leading to the alcohol-induced increase in adiponectin plasma levels.</p></sec><sec><title>Trial registration:</title><p>ClinicalTrials.gov ID no.: NCT00285909</p></sec><sec><title>Funding:</title><p>Partly funded by the Dutch Foundation for Alcohol Research (SAR).</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Adiponectin</kwd><kwd>Alcohol consumption</kwd><kwd>Gene expression</kwd><kwd>High molecular weight adiponectin</kwd><kwd>Insulin sensitivity</kwd><kwd>Lipid profile</kwd><kwd>Peroxisome proliferator-activated receptor gamma</kwd><kwd>Postmenopausal women</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2008</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Moderate alcohol consumption has consistently been associated with a decreased risk of type 2 diabetes compared with abstaining and excessive drinking [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The reason for the lower risk of type 2 diabetes is not entirely clear but a plausible explanation seems to be improved insulin sensitivity [<xref ref-type="bibr" rid="CR3">3</xref>]. However, so far only one randomised controlled trial among postmenopausal women has confirmed this notion [<xref ref-type="bibr" rid="CR4">4</xref>]. Other studies, mainly performed among young male populations, failed to detect such effects [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Adiponectin, an adipose tissue-derived hormone, is thought to play an important role in the regulation of insulin sensitivity and glucose and lipid metabolism [<xref ref-type="bibr" rid="CR13">13</xref>]. Its plasma levels are positively associated with insulin sensitivity [<xref ref-type="bibr" rid="CR14">14</xref>] and are inversely associated with impaired glucose metabolism and type 2 diabetes [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, observational studies revealed an association between moderate alcohol consumption, adiponectin concentrations and insulin sensitivity [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Randomised controlled trials also showed a significant increase in the circulating levels of both total and high molecular weight (HMW) adiponectin [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>] after a period of moderate alcohol consumption compared with abstention.</p><p>However, the mechanism by which moderate alcohol consumption increases adiponectin levels is unknown. Synthesis of adiponectin is controlled by peroxisome proliferator-activated receptor &#x003b3; (PPAR-&#x003b3;) activation, which functions as a transcriptional regulator [<xref ref-type="bibr" rid="CR20">20</xref>]. Low doses of alcohol have been shown to alter the expression of the genes encoding tissue plasminogen activator (<italic>PLAT</italic>) and plasminogen activator inhibitor type-1 (<italic>PAI-1</italic> also known as <italic>SERPINE1</italic>) [<xref ref-type="bibr" rid="CR21">21</xref>]. Like adiponectin, these markers are affected by moderate alcohol consumption and activated by PPAR-&#x003b3; [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>Consequently, we investigated whether moderate alcohol consumption affects expression of the gene encoding adiponectin (<italic>ADIPOQ</italic>) and levels of the protein, and whether it improves insulin sensitivity in postmenopausal women.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p><bold>Study protocol</bold> The study used a randomised, open label, placebo-controlled, crossover design, consisting of two 6&#x000a0;week periods, each preceded by 1&#x000a0;week of washout. Participants consumed 250&#x000a0;ml of white wine (25&#x000a0;g alcohol; Chardonnay; Jean d&#x02019;Alibert, Rieux, France) or alcohol-free white grape juice (Albert Heijn, Zaandam, the Netherlands) daily for 6&#x000a0;weeks during dinner. The study was conducted at TNO (a Dutch acronym for the Netherlands organisation for applied scientific research) Quality of Life, Zeist, the Netherlands. The primary objective of the study was to investigate the effect of moderate alcohol consumption on PPAR-&#x003b3; activity and risk markers of metabolic disease, and it took place between March and June 2006. Participants were instructed to maintain their habitual body weight, food pattern and physical activity pattern and were told to refrain from any alcoholic products during the entire study (including washout periods) except for alcoholic beverages supplied by TNO. Of the 77 women who were screened, 40 were eligible to participate. A total of 36 women were randomly selected and initiated the study. Allocation to treatment order was randomised according to BMI. Both white wine and white grape juice contained 300&#x000a0;kJ/100&#x000a0;ml (&#x0223c;70&#x000a0;kcal/100&#x000a0;ml). Blood and adipose tissue sampling was done on the last day of each treatment period after an overnight fast. Compliance was monitored by weekly measurement of urinary ethyl glucuronide (EtG), a direct phase II metabolite of ethanol formed by the action of UDP-glucuronosyl transferase. EtG has been reported to be a superior marker, with 100% sensitivity as a biomarker of recent drinking [<xref ref-type="bibr" rid="CR23">23</xref>]. It persists in the urine up to &#x0223c;75&#x02013;85&#x000a0;h after the last intake. Additional measures of compliance were an increase in HDL-cholesterol, daily questionnaires, and return of empty bottles.</p><p><bold>Participants</bold> Postmenopausal women were recruited from a pool of volunteers from TNO Quality of Life and by advertisements in local newspapers. Eligible participants consumed between 5 and 21 units of alcohol per week, were apparently healthy and had an absence of menses for at least 2&#x000a0;years, a BMI between 18.5 and 35&#x000a0;kg/m<sup>2</sup> and no family history of alcoholism. Participants gave written informed consent and received compensation for their participation. An independent medical ethics committee (The Medical Ethics Committee of the University Medical Centre Utrecht) approved the research protocol.</p><p><bold>Outcome measures</bold> Primary endpoints were markers of insulin sensitivity, such as homeostasis model assessment of insulin resistance (HOMA-IR), calculated as [fasting serum insulin (in &#x003bc;U/l) &#x000d7; fasting serum glucose (in mmol/l)]/22.5 [<xref ref-type="bibr" rid="CR5">5</xref>], glucose, insulin, and several adiponectin-related measures, such as <italic>ADIPOQ</italic> mRNA levels and plasma levels of total and HMW adiponectin. Secondary variables included lipid profile (triacylglycerol and HDL- and LDL-cholesterol) HbA<sub>1c</sub> and NEFA and correlations between specific outcome measures.</p><p><bold>Analyses and assessment</bold> Ethyl glucuronide was determined in morning urine samples. Urinary samples were diluted about 20-fold using an internal standard solution. The resulting solution was analysed using a triple quadrupole Ultra Performance LC/MS in MRM mode (Waters, Saint-Quentin en Yvelines, France) with a detection limit of 50&#x000a0;ng/ml. The cut-off limit to assess compliance during juice intervention for urinary EtG values was set at &#x0003e;0.25&#x000a0;mg/ml (positive sample), to obtain high sensitivity but avoid positive results due to unintentional ethanol exposure. The cut-off limit during wine intervention was set at EtG &#x0003c;0.5&#x000a0;mg/ml (2.2&#x000a0;&#x003bc;mol/l) (negative sample), as proposed by Bottcher et al. [<xref ref-type="bibr" rid="CR24">24</xref>]. Blood samples were obtained from the antecubital vein of the forearm and collected in tubes containing clot activator for serum and in ice-chilled tubes containing or potassium ethylenediamine tetraacetic acid (K<sub>3</sub>EDTA) for plasma (Vacutainer Systems, Becton Dickinson, Plymouth, UK). Blood was centrifuged for 15&#x000a0;min at 2,000&#x000d7;<italic>g</italic> at 4&#x000b0;C within 15&#x02013;30&#x000a0;min after collection and stored at &#x02212;80&#x000b0;C. All biochemical determinations in blood were performed at TNO Quality of Life using Olympus analytical equipment and reagents except for adiponectin. Plasma total adiponectin concentrations were determined by RIA (Linco Research, St Charles, MO, USA) with a mean intra-assay coefficient of variation of 5.0%, and plasma HMW adiponectin levels were determined by a novel ELISA (Linco Research) with a mean intra-assay coefficient of variation of 14.1%. LDL-cholesterol was calculated using the Friedewald formula. Subcutaneous adipose tissue was sampled from the buttock by means of a Strauss cannula, outer diameter 1.5&#x000a0;mm, and stored at &#x02212;70&#x000b0;C until further analysis. Total RNA was extracted from adipose tissue with TRIzol reagent (Invitrogen, Breda, the Netherlands); 1&#x000a0;mg total RNA was then reverse-transcribed with iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA was PCR-amplified with Platinum Taq DNA polymerase (Invitrogen) on an iCycler (Bio-Rad) or MyIQ (Bio-Rad) PCR machine. Expression was standardised to the level of acidic ribosomal protein <italic>ARBP</italic> [<xref ref-type="bibr" rid="CR25">25</xref>]. Primer sequences used were as follows: <italic>ADIPOQ</italic> forward, TATCCCCAACATGCCCATTCG; <italic>ADIPOQ</italic> reverse, TGGTAGGCAAAGTAGTACAGCC; <italic>PPARG</italic> forward, TCCATGCTGTTATGGGTGAA; <italic>PPARG</italic> reverse, TCAAAGGAGTGGGAGTGGTC; <italic>ARBP</italic> forward, CGGGAAGGCTGTGGTGCTG; <italic>ARBP</italic> reverse, GTGAACACAAAGCCCACATTCC.</p><p><bold>Statistical analyses</bold> Statistical analyses were performed using the SAS statistical software package (SAS version 8; SAS Institute, Cary, NC, USA). All variables were compared between treatments with a mixed analysis of variance model that included terms for treatment, period and the interaction between period and treatment (indicating possible carryover effects). Body weight was included in the model as a random factor to adjust for changes in body weight. Correlation coefficients were computed according to Spearman rank order to assess associations between intervention-induced changes in outcome measures. Based on a study by Arvidsson et al. [<xref ref-type="bibr" rid="CR26">26</xref>], a sample size of 36 was considered sufficient to detect a 20% difference in <italic>ADIPOQ</italic> mRNA levels with a power of 80%, accepting a two-sided <italic>&#x003b1;</italic> of 0.05. Data are presented as mean&#x02009;&#x000b1;&#x02009;SEM unless otherwise specified. Statistical significance was defined as <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p><bold>General results</bold> All 36 postmenopausal women completed the study. Participants were slightly overweight (BMI 25.4&#x02009;&#x000b1;&#x02009;3.3&#x000a0;kg/m<sup>2</sup>). Mean glucose, insulin, triacylglycerol and cholesterol concentrations before the intervention indicated that participants were euglycaemic and normolipidaemic (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Characteristics of 36 postmenopausal women before intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th align="left">Baseline value</th></tr></thead><tbody><tr><td>Age (years)</td><td char="&#x000b1;" align="char">56.5&#x02009;&#x000b1;&#x02009;4.2</td></tr><tr><td>Weight (kg)</td><td char="&#x000b1;" align="char">71.4&#x02009;&#x000b1;&#x02009;10.0</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td char="&#x000b1;" align="char">25.4&#x02009;&#x000b1;&#x02009;3.3</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#x000b1;" align="char">5.5 &#x02009;&#x000b1;&#x02009;0.4</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#x000b1;" align="char">37.4&#x02009;&#x000b1;&#x02009;12.6</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#x000b1;" align="char">1.21&#x02009;&#x000b1;&#x02009;0.54</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#x000b1;" align="char">1.67&#x02009;&#x000b1;&#x02009;0.27</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#x000b1;" align="char">3.88&#x02009;&#x000b1;&#x02009;0.60</td></tr><tr><td>Total cholesterol (mmol/l)</td><td char="&#x000b1;" align="char">6.11&#x02009;&#x000b1;&#x02009;0.72</td></tr><tr><td>Alkaline phosphatase (U/l)</td><td char="&#x000b1;" align="char">76.1&#x02009;&#x000b1;&#x02009;19.3</td></tr><tr><td>Alanine aminotransferase (U/l)</td><td char="&#x000b1;" align="char">15.3&#x02009;&#x000b1;&#x02009;8.2</td></tr><tr><td>Aspartate aminotransferase (U/l)</td><td char="&#x000b1;" align="char">20.8&#x02009;&#x000b1;&#x02009;7.4</td></tr><tr><td>&#x003b3;-Glutamyltranspeptidase (U/l)</td><td char="&#x000b1;" align="char">21.3&#x02009;&#x000b1;&#x02009;11.4</td></tr><tr><td>Follicle-stimulating hormone (IU/l)</td><td char="&#x000b1;" align="char">108.5&#x02009;&#x000b1;&#x02009;41.3</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x02009;&#x000b1;&#x02009;SD</p></table-wrap-foot></table-wrap></p><p>Compliance with treatments was assessed by weekly urinary EtG, revealing two positive samples during the juice-drinking period and six negative samples during the wine-drinking period out of the 468 samples analysed (overall compliance 98.3%). Another indicator of compliance was the 7.0% higher level of HDL-cholesterol after wine consumption compared with the value after juice consumption (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Markers of insulin sensitivity, adiponectin and lipid profile in 36 postmenopausal women measured at the end of a 6&#x000a0;week period of consuming white grape juice or white wine</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th align="left">Grape juice</th><th align="left">White wine</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Insulin sensitivity</td></tr><tr><td>HOMA-IR</td><td char="&#x000b1;" align="char">1.64&#x02009;&#x000b1;&#x02009;0.13</td><td char="&#x000b1;" align="char">1.42&#x02009;&#x000b1;&#x02009;0.13</td><td char="." align="char">0.02</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#x000b1;" align="char">46.5&#x02009;&#x000b1;&#x02009;3.4</td><td char="&#x000b1;" align="char">40.0&#x02009;&#x000b1;&#x02009;3.4</td><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#x000b1;" align="char">5.4&#x02009;&#x000b1;&#x02009;0.1</td><td char="&#x000b1;" align="char">5.4&#x02009;&#x000b1;&#x02009;0.1</td><td char="." align="char">0.72</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td char="&#x000b1;" align="char">6.0&#x02009;&#x000b1;&#x02009;0.04</td><td char="&#x000b1;" align="char">5.9&#x02009;&#x000b1;&#x02009;0.04</td><td char="." align="char">0.09</td></tr><tr><td>Fasting NEFA (mmol/l)</td><td char="&#x000b1;" align="char">0.43&#x02009;&#x000b1;&#x02009; 0.04</td><td char="&#x000b1;" align="char">0.44&#x02009;&#x000b1;&#x02009;0.04</td><td char="." align="char">0.67</td></tr><tr><td>Body weight (kg)</td><td char="&#x000b1;" align="char">70.4&#x02009;&#x000b1;&#x02009;1.7</td><td char="&#x000b1;" align="char">71.1&#x02009;&#x000b1;&#x02009;1.7</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td colspan="4">Adiponectin</td></tr><tr><td><italic>ADIPOQ</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#x000b1;" align="char">0.98&#x02009;&#x000b1;&#x02009;0.15</td><td char="&#x000b1;" align="char">1.09&#x02009;&#x000b1;&#x02009;0.15</td><td char="." align="char">0.04</td></tr><tr><td><italic>PPARG</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#x000b1;" align="char">0.67&#x02009;&#x000b1;&#x02009;0.09</td><td char="&#x000b1;" align="char">0.73&#x02009;&#x000b1;&#x02009;0.09</td><td char="." align="char">0.13</td></tr><tr><td>Fasting total adiponectin (&#x003bc;g/ml)</td><td char="&#x000b1;" align="char">12.0&#x02009;&#x000b1;&#x02009;0.8</td><td char="&#x000b1;" align="char">13.1&#x02009;&#x000b1;&#x02009;0.8</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td>Fasting HMW adiponectin (&#x003bc;g/ml)</td><td char="&#x000b1;" align="char">8.8&#x02009;&#x000b1;&#x02009;1.2</td><td char="&#x000b1;" align="char">9.9&#x02009;&#x000b1;&#x02009;1.2</td><td char="." align="char">0.02</td></tr><tr><td colspan="4">Lipid profile</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#x000b1;" align="char">1.18&#x02009;&#x000b1;&#x02009;0.08</td><td char="&#x000b1;" align="char">1.03&#x02009;&#x000b1;&#x02009;0.08</td><td char="." align="char">0.04</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#x000b1;" align="char">1.57&#x02009;&#x000b1;&#x02009;0.04</td><td char="&#x000b1;" align="char">1.68&#x02009;&#x000b1;&#x02009;0.04</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#x000b1;" align="char">3.84&#x02009;&#x000b1;&#x02009;0.12</td><td char="&#x000b1;" align="char">3.51&#x02009;&#x000b1;&#x02009;0.12</td><td char="." align="char">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x02009;&#x000b1;&#x02009;SEM</p></table-wrap-foot></table-wrap></p><p>No significant (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05) carryover effects, as assessed by interaction between treatment and period effects, were observed for any outcome measures. Treatment means of variables and <italic>p</italic> values estimated from models with period effects were very similar to those obtained from models without a period effect, and we report the results of the latter. Mean body weight was 0.7&#x000a0;kg higher (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) at the end of the wine-drinking period than at the end of the juice-drinking period (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Results were adjusted for this difference in body weight but did not essentially change them. Therefore, unadjusted results are presented here.</p><p><bold>Insulin sensitivity</bold> Fasting serum insulin concentration was lower (by 12.3%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and the HbA<sub>1c</sub> percentage tended to be lower (<italic>p</italic>&#x02009;=&#x02009;0.09) after 6&#x000a0;weeks of moderate alcohol consumption than after 6&#x000a0;weeks of abstention. Insulin sensitivity, as expressed by the HOMA-IR index, improved by 11.9% (<italic>p</italic>&#x02009;=&#x02009;0.02) after white wine consumption compared with that following juice consumption. However, serum glucose and NEFA concentrations did not differ significantly between the two interventions at the end of the intervention period (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p><bold>Adiponectin</bold> There was a significant increase in the relative <italic>ADIPOQ</italic> mRNA levels in subcutaneous adipose tissue (27.7%; <italic>p</italic>&#x02009;=&#x02009;0.04) of women who consumed alcohol in moderation for 6&#x000a0;weeks compared with those who consumed juice. Consistently, the ratio of <italic>PPARG</italic>/<italic>ARBP</italic> mRNA levels also tended to increase, although not significantly (<italic>p</italic>&#x02009;=&#x02009;0.13), after the alcohol treatment. Plasma protein levels of total adiponectin (10.6%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and HMW adiponectin (15.8%; <italic>p</italic>&#x02009;=&#x02009;0.02) increased significantly after consuming white wine, rather than juice, for 6 weeks (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p><bold>Lipid profile</bold> Besides a significant increase in HDL-cholesterol, changes in lipid profile were further characterised by significantly lower levels of LDL-cholesterol (7.8%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and triacylglycerol (8.2%; <italic>p</italic>&#x02009;=&#x02009;0.04) after the wine-drinking period compared with the juice-drinking period (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p><bold>Correlations</bold> Changes in <italic>ADIPOQ</italic> mRNA levels due to alcohol consumption correlated positively with changes in <italic>PPARG</italic> mRNA levels (&#x003c1;&#x02009;=&#x02009;0.76; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and with changes in the plasma protein level of total adiponectin (&#x003c1;&#x02009;=&#x02009;0.46; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), but not with changes in plasma levels of HMW adiponectin (&#x003c1;&#x02009;=&#x02009;&#x02212;0.25; <italic>p</italic>&#x02009;=&#x02009;0.15). No significant correlations were found between changes in HOMA-IR and changes in plasma levels of total adiponectin (&#x003c1;&#x02009;=&#x02009;0.27; <italic>p</italic>&#x02009;=&#x02009;0.11) or HMW adiponectin (&#x003c1;&#x02009;=&#x02009;&#x02212;0.18; <italic>p</italic>&#x02009;=&#x02009;0.29). Furthermore, changes in HDL-cholesterol correlated significantly with changes in total adiponectin (&#x003c1;&#x02009;=&#x02009;0.47; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) but not with HMW adiponectin levels (<italic>&#x003c1;</italic>&#x02009;=&#x02009;0.13; <italic>p</italic>&#x02009;=&#x02009;0.44).</p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>The primary findings of this study are that daily, moderate alcohol intake improves insulin sensitivity and lipid profile in postmenopausal women. Furthermore, <italic>ADIPOQ</italic> mRNA levels in subcutaneous adipose tissue along with plasma levels of total and HMW adiponectin increased after moderate alcohol consumption. Moreover, changes in <italic>ADIPOQ</italic> mRNA levels correlated with changes in plasma total adiponectin, indicating that prolonged moderate alcohol intake increases circulating adiponectin through increased gene expression. However, improvements in insulin sensitivity were not associated with increased plasma adiponectin levels (HMW and total) after moderate alcohol consumption in these women.</p><p>A strength of this study is its randomised crossover design. Another strength is that we assessed compliance to study treatment several times in different ways throughout the study and observed no significant deviations. Several limitations warrant consideration. A slightly lower body weight was observed after the juice intervention compared with the alcohol intervention. However, lower body weight is associated with improved insulin sensitivity and thus could have only affected the results towards no alcohol-induced improvement in insulin sensitivity. In the present study, only subcutaneous adipose tissue samples were used to determine <italic>ADIPOQ</italic> mRNA levels. Studies demonstrated that <italic>ADIPOQ</italic> mRNA levels were higher [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] or not different [<xref ref-type="bibr" rid="CR29">29</xref>] in subcutaneous compared with visceral adipose tissue in lean and obese participants. Furthermore, studies in human adipose tissue showed increased [<xref ref-type="bibr" rid="CR30">30</xref>] as well as similar [<xref ref-type="bibr" rid="CR31">31</xref>] <italic>ADIPOQ</italic> mRNA and in vitro adiponectin secretion levels from subcutaneous compared with omental adipocytes. Subcutaneous adipose tissue thus appears to be at least as important as omental adipose tissue for circulating plasma adiponectin levels.</p><p>The observed changes in insulin sensitivity after prolonged moderate alcohol intake are in accordance with a study by Davies et al. [<xref ref-type="bibr" rid="CR4">4</xref>] in which moderate alcohol consumption in postmenopausal women for 8&#x000a0;weeks decreased fasting insulin and triacylglycerol levels&#x02014;both independent risk factors for type 2 diabetes&#x02014;and improved insulin sensitivity. However, other clinical trials did not find a change in fasting insulin levels [<xref ref-type="bibr" rid="CR9">9</xref>] and triacylglycerol levels [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] or in insulin sensitivity after moderate alcohol consumption [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], whereas levels of total adiponectin [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] and HMW adiponectin [<xref ref-type="bibr" rid="CR8">8</xref>] did increase. Differences in the designs used in these clinical trials are numerous. However, studies that did observe an effect on markers of insulin sensitivity after moderate alcohol consumption were all performed in middle-aged [<xref ref-type="bibr" rid="CR4">4</xref>], relatively insulin-resistant [<xref ref-type="bibr" rid="CR6">6</xref>] or diabetic people [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. This suggests that the effect of moderate alcohol intake on insulin sensitivity is more pronounced in people with (slightly) impaired glucose tolerance rather than young and glucose-tolerant people. Moreover, most interventions that did not observe a link between alcohol and insulin sensitivity involved only 30 [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] or even fewer [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR11">11</xref>] days of consecutive alcohol consumption, while this study and the studies of Davies et al. [<xref ref-type="bibr" rid="CR4">4</xref>] and Shai et al. [<xref ref-type="bibr" rid="CR34">34</xref>] lasted 6, 8 and 12&#x000a0;weeks respectively. This indicates that a longer duration of alcohol consumption may be needed to exert an effect on insulin sensitivity. Finally, the relation between moderate alcohol intake and insulin sensitivity might be influenced by sex, since the association between alcohol consumption and type 2 diabetes appears to be stronger in women than in men, as observed in some observational studies [<xref ref-type="bibr" rid="CR1">1</xref>]. This sex difference may be explained partly by changes associated with menopause, which may mediate the relation between alcohol and triacylglycerol levels, the latter being an independent risk factor for type 2 diabetes [<xref ref-type="bibr" rid="CR36">36</xref>]. Compared with postmenopausal non-drinkers, postmenopausal drinkers have lower triacylglycerol levels, whereas male drinkers have higher triacylglycerol levels compared with male abstainers [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>Intervention-associated changes in <italic>ADIPOQ</italic> mRNA in subcutaneous adipose tissue correlated with changes in plasma protein levels of total adiponectin. In line with this are cross-sectional studies [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] showing associations between subcutaneous <italic>ADIPOQ</italic> mRNA levels and plasma levels of adiponectin. This finding suggests that the alcohol-induced increase in plasma adiponectin levels is mediated by de novo synthesis rather than decreased renal function [<xref ref-type="bibr" rid="CR40">40</xref>] or post-transcriptional regulation [<xref ref-type="bibr" rid="CR41">41</xref>]. Changes in plasma HMW adiponectin did not correlate with changes in <italic>ADIPOQ</italic> mRNA levels. However, the formation of multimer oligomers of HMW adiponectin is influenced by several post-translational modifications [<xref ref-type="bibr" rid="CR42">42</xref>], which can account for the absence of such a correlation.</p><p>Adiponectin synthesis is under the control of the transcription factor PPAR-&#x003b3; [<xref ref-type="bibr" rid="CR20">20</xref>]. PPAR-&#x003b3; ligands induce expression of <italic>ADIPOQ</italic> via direct binding of the PPAR-&#x003b3;/retinoid X receptor heterodimer to the PPAR-responsive element in the human <italic>ADIPOQ</italic> promoter. We indeed observed a trend for increased <italic>PPARG</italic> mRNA levels after the alcohol intervention. However, our sample size of 36 participants was anticipated to detect a 20% change in mRNA levels. As the intervention gave rise to a change of only 9% in <italic>PPARG</italic> mRNA, our study was underpowered to detect a significant difference. Besides this trend for increased PPAR levels, we also found a strong correlation between intervention-associated changes in levels of <italic>PPARG</italic> and <italic>ADIPOQ</italic> mRNAs. Furthermore, previous research has shown that <italic>PAI-1</italic> expression and PAI-1 protein levels increase after alcohol consumption [<xref ref-type="bibr" rid="CR21">21</xref>]. <italic>PAI-1</italic> expression is also regulated by PPAR-&#x003b3; [<xref ref-type="bibr" rid="CR22">22</xref>]. It thus seems plausible that moderate alcohol use might alter <italic>ADIPOQ</italic> expression and, consequently, adiponectin protein levels, also in a PPAR-&#x003b3;-mediated manner.</p><p>Consistent with previous findings in young and middle-aged men [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], we now report that total adiponectin plasma levels also increase in postmenopausal women after moderate alcohol consumption. Moreover, we found that the HMW form of plasma adiponectin also increased after 6&#x000a0;weeks of alcohol consumption. The increase in HMW adiponectin after moderate alcohol consumption is in line with a previous study in which a trend was observed [<xref ref-type="bibr" rid="CR8">8</xref>]. In the present study, however, we used a more sensitive and precise method to quantify HMW adiponectin&#x02014;ELISA instead of quantitative western blotting.</p><p>The observed changes in insulin sensitivity as measured by HOMA-IR did not correlate with the alcohol-induced changes in total or HMW adiponectin, the latter of which is proposed to be a better predictor of insulin sensitivity [<xref ref-type="bibr" rid="CR43">43</xref>]. These findings are consistent with other lifestyle interventions, such as weight loss [<xref ref-type="bibr" rid="CR44">44</xref>] and exercise interventions [<xref ref-type="bibr" rid="CR45">45</xref>], and with previous observations of our group [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] which showed increased adiponectin plasma levels without changes in insulin sensitivity. In this study we did find an effect of alcohol on insulin sensitivity irrespective of changes in adiponectin levels. The present results may suggest a possible independent effect of alcohol on insulin sensitivity in addition to an adiponectin-mediated effect on insulin sensitivity.</p><p>Looking at our cross-sectional data, we did observe correlations between HOMA-IR and adiponectin levels after both alcohol and placebo treatment (data not shown). This is in line with published literature in which associations between adiponectin and insulin sensitivity have been shown consistently [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Possibly, increased adiponectin levels partly explain the improved insulin sensitivity seen among moderate alcohol consumers [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Studies have revealed that circulating adiponectin levels are inversely associated with markers of inflammation [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], whereas low-grade inflammation is thought to contribute to insulin resistance [<xref ref-type="bibr" rid="CR48">48</xref>]. Therefore, adiponectin may lead to improved insulin sensitivity through effects on inflammatory markers.</p><p>In conclusion, the results of the present study demonstrate that 6&#x000a0;weeks of moderate alcohol consumption improves insulin sensitivity and the lipid profile in postmenopausal women. Furthermore, moderate alcohol consumption increases subcutaneous adipose <italic>ADIPOQ</italic> mRNA levels and plasma levels of adiponectin. This suggests that the alcohol-induced increase in adiponectin is attributable, at least in part, to transcriptional alterations in adipose tissue. The observed improvements in insulin sensitivity, lipid profile and adiponectin levels when consuming 2.5 standard drinks per day may reduce the risk of type 2 diabetes and cardiovascular disease in postmenopausal women. Despite these potentially beneficial findings, the scientific literature indicates that alcohol drinking may also have detrimental effects on health [<xref ref-type="bibr" rid="CR49">49</xref>]. Both potential benefits and risks should be taken into consideration when counselling people about consumption.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank all those involved in the conduct of the study for their efforts. The research described in this article was partly funded by the Dutch Foundation for Alcohol Research (SAR).</p><p><bold>Duality of interest</bold> The authors declare that there is no duality of interest associated with this manuscript.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution-Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koppes</surname><given-names>LLJ</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name><name><surname>Hendriks</surname><given-names>HFJ</given-names></name><name><surname>Bouter</surname><given-names>LM</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name></person-group><article-title>Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.3.719</pub-id></citation><citation citation-type="display-unstructured">Koppes LLJ, Dekker JM, Hendriks HFJ, Bouter LM, Heine RJ (2005) Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care 28:719&#x02013;725 <pub-id pub-id-type="pmid">15735217</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beulens</surname><given-names>JWJ</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Schouw</surname><given-names>YT</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Hendriks</surname><given-names>HFJ</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name></person-group><article-title>alcohol consumption and risk of type 2 diabetes among older women</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>2933</fpage><lpage>2938</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.12.2933</pub-id></citation><citation citation-type="display-unstructured">Beulens JWJ, Stolk RP, van der Schouw YT, Grobbee DE, Hendriks HFJ, Bots ML (2005) alcohol consumption and risk of type 2 diabetes among older women. Diabetes Care 28:2933&#x02013;2938 <pub-id pub-id-type="pmid">16306557</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>HF</given-names></name></person-group><article-title>Moderate alcohol consumption and insulin sensitivity: observations and possible mechanisms</article-title><source>Ann Epidemiol</source><year>2007</year><volume>17</volume><fpage>S40</fpage><lpage>S42</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2007.01.009</pub-id></citation><citation citation-type="display-unstructured">Hendriks HF (2007) Moderate alcohol consumption and insulin sensitivity: observations and possible mechanisms. Ann Epidemiol 17:S40&#x02013;S42 </citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Baer</surname><given-names>DJ</given-names></name><name><surname>Judd</surname><given-names>JT</given-names></name><name><surname>Brown</surname><given-names>ED</given-names></name><name><surname>Campbell</surname><given-names>WS</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name></person-group><article-title>Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>2559</fpage><lpage>2562</lpage><pub-id pub-id-type="doi">10.1001/jama.287.19.2559</pub-id></citation><citation citation-type="display-unstructured">Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR (2002) Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 287:2559&#x02013;2562 <pub-id pub-id-type="pmid">12020337</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zilkens</surname><given-names>RR</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name><name><surname>Watts</surname><given-names>G</given-names></name><name><surname>Beilin</surname><given-names>LJ</given-names></name><name><surname>Puddey</surname><given-names>IB</given-names></name></person-group><article-title>The effect of alcohol intake on insulin sensitivity in men: a randomized controlled trial</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>608</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.3.608</pub-id></citation><citation citation-type="display-unstructured">Zilkens RR, Burke V, Watts G, Beilin LJ, Puddey IB (2003) The effect of alcohol intake on insulin sensitivity in men: a randomized controlled trial. Diabetes Care 26:608&#x02013;612 <pub-id pub-id-type="pmid">12610009</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sierksma</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-&#x003b1;, and insulin sensitivity</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.1.184</pub-id></citation><citation citation-type="display-unstructured">Sierksma A, Patel H, Ouchi N et al (2004) Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-&#x003b1;, and insulin sensitivity. Diabetes Care 27:184&#x02013;189 <pub-id pub-id-type="pmid">14693987</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="other">Beulens JWJ, de Zoete EC, Kok FJ, Schaafsma G, Hendriks HFJ (2008) Effect of moderate alcohol consumption on adipokines and insulin sensitivity in lean and overweight men: a diet intervention study. Eur J Clin Nutr DOI dx.doi.org/10.1038/sj.ejcn.1602821</citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beulens</surname><given-names>J</given-names></name><name><surname>Loon</surname><given-names>L</given-names></name><name><surname>Kok</surname><given-names>F</given-names></name><etal/></person-group><article-title>The effect of moderate alcohol consumption on adiponectin oligomers and muscle oxidative capacity: a human intervention study</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><fpage>1388</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1007/s00125-007-0699-8</pub-id></citation><citation citation-type="display-unstructured">Beulens J, van Loon L, Kok F et al (2007) The effect of moderate alcohol consumption on adiponectin oligomers and muscle oxidative capacity: a human intervention study. Diabetologia 50:1388&#x02013;1392 <pub-id pub-id-type="pmid">17492425</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cordain</surname><given-names>L</given-names></name><name><surname>Bryan</surname><given-names>ED</given-names></name><name><surname>Melby</surname><given-names>CL</given-names></name><name><surname>Smith</surname><given-names>MJ</given-names></name></person-group><article-title>Influence of moderate daily wine consumption on body weight regulation and metabolism in healthy free-living males</article-title><source>J Am Coll Nutr</source><year>1997</year><volume>16</volume><fpage>134</fpage><lpage>139</lpage></citation><citation citation-type="display-unstructured">Cordain L, Bryan ED, Melby CL, Smith MJ (1997) Influence of moderate daily wine consumption on body weight regulation and metabolism in healthy free-living males. J Am Coll Nutr 16:134&#x02013;139 <pub-id pub-id-type="pmid">9100213</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cordain</surname><given-names>L</given-names></name><name><surname>Melby</surname><given-names>CL</given-names></name><name><surname>Hamamoto</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Influence of moderate chronic wine consumption on insulin sensitivity and other correlates of syndrome X in moderately obese women</article-title><source>Metabolism</source><year>2000</year><volume>49</volume><fpage>1473</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1053/meta.2000.17672</pub-id></citation><citation citation-type="display-unstructured">Cordain L, Melby CL, Hamamoto AE et al (2000) Influence of moderate chronic wine consumption on insulin sensitivity and other correlates of syndrome X in moderately obese women. Metabolism 49:1473&#x02013;1478 <pub-id pub-id-type="pmid">11092514</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beulens</surname><given-names>JWJ</given-names></name><name><surname>Beers</surname><given-names>RM</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Schaafsma</surname><given-names>G</given-names></name><name><surname>Hendriks</surname><given-names>HFJ</given-names></name></person-group><article-title>The effect of moderate alcohol consumption on fat distribution and adipocytokines</article-title><source>Obesity Res</source><year>2006</year><volume>14</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/oby.2006.8</pub-id></citation><citation citation-type="display-unstructured">Beulens JWJ, van Beers RM, Stolk RP, Schaafsma G, Hendriks HFJ (2006) The effect of moderate alcohol consumption on fat distribution and adipocytokines. Obesity Res 14:60&#x02013;66 </citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Ortiz</surname><given-names>M</given-names></name><name><surname>Pascoe-Gonzalez</surname><given-names>S</given-names></name><name><surname>Kam-Ramos</surname><given-names>AM</given-names></name><name><surname>Martinez-Abundis</surname><given-names>E</given-names></name></person-group><article-title>Effect of tequila on homocysteine, insulin secretion, insulin sensitivity, and metabolic profile in healthy men</article-title><source>J Diabetes Complicat</source><year>2005</year><volume>19</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2004.09.001</pub-id></citation><citation citation-type="display-unstructured">Gonzalez-Ortiz M, Pascoe-Gonzalez S, Kam-Ramos AM, Martinez-Abundis E (2005) Effect of tequila on homocysteine, insulin secretion, insulin sensitivity, and metabolic profile in healthy men. J Diabetes Complicat 19:155&#x02013;159 <pub-id pub-id-type="pmid">15866061</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>SA</given-names></name><name><surname>Ciaraldi</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>RR</given-names></name></person-group><article-title>Adiponectin: more than just another fat cell hormone?</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>2442</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.8.2442</pub-id></citation><citation citation-type="display-unstructured">Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442&#x02013;2450 <pub-id pub-id-type="pmid">12882876</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tschritter</surname><given-names>O</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Thamer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.2.239</pub-id></citation><citation citation-type="display-unstructured">Tschritter O, Fritsche A, Thamer C et al (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239&#x02013;243 <pub-id pub-id-type="pmid">12540592</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snijder</surname><given-names>MB</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><name><surname>Seidell</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>2498</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.2337/dc06-0952</pub-id></citation><citation citation-type="display-unstructured">Snijder MB, Heine RJ, Seidell JC et al (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study. Diabetes Care 29:2498&#x02013;2503 <pub-id pub-id-type="pmid">17065691</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snehalatha</surname><given-names>C</given-names></name><name><surname>Mukesh</surname><given-names>B</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Viswanathan</surname><given-names>V</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Ramachandran</surname><given-names>A</given-names></name></person-group><article-title>Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>3226</fpage><lpage>3229</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.12.3226</pub-id></citation><citation citation-type="display-unstructured">Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A (2003) Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26:3226&#x02013;3229 <pub-id pub-id-type="pmid">14633806</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Schmidt</surname><given-names>MI</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>2473</fpage><lpage>2478</lpage><pub-id pub-id-type="doi">10.2337/diabetes.53.9.2473</pub-id></citation><citation citation-type="display-unstructured">Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 53:2473&#x02013;2478 <pub-id pub-id-type="pmid">15331562</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thamer</surname><given-names>C</given-names></name><name><surname>Haap</surname><given-names>M</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Haering</surname><given-names>H</given-names></name><name><surname>Stumvoll</surname><given-names>M</given-names></name></person-group><article-title>Relationship between moderate alcohol consumption and adiponectin and insulin sensitivity in a large heterogeneous population</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1240</fpage><pub-id pub-id-type="doi">10.2337/diacare.27.5.1240</pub-id></citation><citation citation-type="display-unstructured">Thamer C, Haap M, Fritsche A, Haering H, Stumvoll M (2004) Relationship between moderate alcohol consumption and adiponectin and insulin sensitivity in a large heterogeneous population. Diabetes Care 27:1240 <pub-id pub-id-type="pmid">15111562</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Englund Ogge</surname><given-names>L</given-names></name><name><surname>Brohall</surname><given-names>G</given-names></name><name><surname>Behre</surname><given-names>CJ</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Fagerberg</surname><given-names>B</given-names></name></person-group><article-title>Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old Caucasian women: a population-based study with a focus on impaired glucose regulation</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>908</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.2337/diacare.29.04.06.dc05-1782</pub-id></citation><citation citation-type="display-unstructured">Englund Ogge L, Brohall G, Behre CJ, Schmidt C, Fagerberg B (2006) Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old Caucasian women: a population-based study with a focus on impaired glucose regulation. Diabetes Care 29:908&#x02013;913 <pub-id pub-id-type="pmid">16567836</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwaki</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name><etal/></person-group><article-title>Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>1655</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.7.1655</pub-id></citation><citation citation-type="display-unstructured">Iwaki M, Matsuda M, Maeda N et al (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655&#x02013;1663 <pub-id pub-id-type="pmid">12829629</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Booyse</surname><given-names>FM</given-names></name><name><surname>Aikens</surname><given-names>ML</given-names></name><name><surname>Grenett</surname><given-names>HE</given-names></name></person-group><article-title>Endothelial cell fibrinolysis: transcriptional regulation of fibrinolytic protein gene expression (t-PA, u-PA, and PAI-1) by low alcohol</article-title><source>Alcohol Clin Exp Res</source><year>1999</year><volume>23</volume><fpage>1119</fpage><lpage>1124</lpage></citation><citation citation-type="display-unstructured">Booyse FM, Aikens ML, Grenett HE (1999) Endothelial cell fibrinolysis: transcriptional regulation of fibrinolytic protein gene expression (t-PA, u-PA, and PAI-1) by low alcohol. Alcohol Clin Exp Res 23:1119&#x02013;1124 <pub-id pub-id-type="pmid">10397301</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Bourcier</surname><given-names>T</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Plutzky</surname><given-names>J</given-names></name></person-group><article-title>PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1999</year><volume>19</volume><fpage>546</fpage><lpage>551</lpage></citation><citation citation-type="display-unstructured">Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J (1999) PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19:546&#x02013;551 <pub-id pub-id-type="pmid">10073956</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoiseth</surname><given-names>G</given-names></name><name><surname>Bernard</surname><given-names>JP</given-names></name><name><surname>Stephanson</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment</article-title><source>Alcohol Alcohol</source><year>2008</year><volume>43</volume><fpage>187</fpage><lpage>191</lpage></citation><citation citation-type="display-unstructured">Hoiseth G, Bernard JP, Stephanson N et al (2008) Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment. Alcohol Alcohol 43:187&#x02013;191 <pub-id pub-id-type="pmid">18230699</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bottcher</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>O</given-names></name><name><surname>Helander</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of a new immunoassay for urinary ethyl glucuronide testing</article-title><source>Alcohol Alcohol</source><year>2008</year><volume>43</volume><fpage>46</fpage><lpage>48</lpage></citation><citation citation-type="display-unstructured">Bottcher M, Beck O, Helander A (2008) Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol Alcohol 43:46&#x02013;48 <pub-id pub-id-type="pmid">17942435</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joosen</surname><given-names>AM</given-names></name><name><surname>Bakker</surname><given-names>AH</given-names></name><name><surname>Zorenc</surname><given-names>AH</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>Schrauwen</surname><given-names>P</given-names></name><name><surname>Westerterp</surname><given-names>KR</given-names></name></person-group><article-title>PPARgamma activity in subcutaneous abdominal fat tissue and fat mass gain during short-term overfeeding</article-title><source>Int J Obes (Lond)</source><year>2006</year><volume>30</volume><fpage>302</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0803146</pub-id></citation><citation citation-type="display-unstructured">Joosen AM, Bakker AH, Zorenc AH, Kersten S, Schrauwen P, Westerterp KR (2006) PPARgamma activity in subcutaneous abdominal fat tissue and fat mass gain during short-term overfeeding. Int J Obes (Lond) 30:302&#x02013;307 <pub-id pub-id-type="pmid">16247507</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arvidsson</surname><given-names>E</given-names></name><name><surname>Viguerie</surname><given-names>N</given-names></name><name><surname>Andersson</surname><given-names>I</given-names></name><name><surname>Verdich</surname><given-names>C</given-names></name><name><surname>Langin</surname><given-names>D</given-names></name><name><surname>Arner</surname><given-names>P</given-names></name></person-group><article-title>Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>1966</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.2337/diabetes.53.8.1966</pub-id></citation><citation citation-type="display-unstructured">Arvidsson E, Viguerie N, Andersson I, Verdich C, Langin D, Arner P (2004) Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes 53:1966&#x02013;1971 <pub-id pub-id-type="pmid">15277374</pub-id></citation></ref><ref id="CR27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Morante</surname><given-names>JJ</given-names></name><name><surname>Milagro</surname><given-names>F</given-names></name><name><surname>Gabaldon</surname><given-names>JA</given-names></name><name><surname>Martinez</surname><given-names>JA</given-names></name><name><surname>Zamora</surname><given-names>S</given-names></name><name><surname>Garaulet</surname><given-names>M</given-names></name></person-group><article-title>Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans</article-title><source>Eur J Endocrinol</source><year>2006</year><volume>155</volume><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1530/eje.1.02256</pub-id></citation><citation citation-type="display-unstructured">Hernandez-Morante JJ, Milagro F, Gabaldon JA, Martinez JA, Zamora S, Garaulet M (2006) Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur J Endocrinol 155:593&#x02013;600 <pub-id pub-id-type="pmid">16990659</pub-id></citation></ref><ref id="CR28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lihn</surname><given-names>AS</given-names></name><name><surname>Bruun</surname><given-names>JM</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Pedersen</surname><given-names>SB</given-names></name><name><surname>Jensen</surname><given-names>PF</given-names></name><name><surname>Richelsen</surname><given-names>B</given-names></name></person-group><article-title>Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects</article-title><source>Mol Cell Endocrinol</source><year>2004</year><volume>219</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2004.03.002</pub-id></citation><citation citation-type="display-unstructured">Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B (2004) Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219:9&#x02013;15 <pub-id pub-id-type="pmid">15149722</pub-id></citation></ref><ref id="CR29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women</article-title><source>Int J Obes Relat Metab Disord</source><year>2003</year><volume>27</volume><fpage>896</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0802367</pub-id></citation><citation citation-type="display-unstructured">Yang WS, Chen MH, Lee WJ et al (2003) Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int J Obes Relat Metab Disord 27:896&#x02013;900 <pub-id pub-id-type="pmid">12861229</pub-id></citation></ref><ref id="CR30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>FM</given-names></name><name><surname>McTernan</surname><given-names>PG</given-names></name><name><surname>Valsamakis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status</article-title><source>Horm Metab Res</source><year>2002</year><volume>34</volume><fpage>650</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1055/s-2002-38246</pub-id></citation><citation citation-type="display-unstructured">Fisher FM, McTernan PG, Valsamakis G et al (2002) Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 34:650&#x02013;654 <pub-id pub-id-type="pmid">12660876</pub-id></citation></ref><ref id="CR31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motoshima</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Sinha</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>5662</fpage><lpage>5667</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-020635</pub-id></citation><citation citation-type="display-unstructured">Motoshima H, Wu X, Sinha MK et al (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662&#x02013;5667 <pub-id pub-id-type="pmid">12466369</pub-id></citation></ref><ref id="CR32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rumpler</surname><given-names>WV</given-names></name><name><surname>Clevidence</surname><given-names>BA</given-names></name><name><surname>Muesing</surname><given-names>RA</given-names></name><name><surname>Rhodes</surname><given-names>DG</given-names></name></person-group><article-title>Changes in women&#x02019;s plasma lipid and lipoprotein concentrations due to moderate consumption of alcohol are affected by dietary fat level</article-title><source>J Nutr</source><year>1999</year><volume>129</volume><fpage>1713</fpage><lpage>1717</lpage></citation><citation citation-type="display-unstructured">Rumpler WV, Clevidence BA, Muesing RA, Rhodes DG (1999) Changes in women&#x02019;s plasma lipid and lipoprotein concentrations due to moderate consumption of alcohol are affected by dietary fat level. J Nutr 129:1713&#x02013;1717 <pub-id pub-id-type="pmid">10460209</pub-id></citation></ref><ref id="CR33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sierksma</surname><given-names>A</given-names></name><name><surname>Vermunt</surname><given-names>SH</given-names></name><name><surname>Lankhuizen</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Effect of moderate alcohol consumption on parameters of reverse cholesterol transport in postmenopausal women</article-title><source>Alcohol Clin Exp Res</source><year>2004</year><volume>28</volume><fpage>662</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1097/01.ALC.0000122763.30770.F5</pub-id></citation><citation citation-type="display-unstructured">Sierksma A, Vermunt SH, Lankhuizen IM et al (2004) Effect of moderate alcohol consumption on parameters of reverse cholesterol transport in postmenopausal women. Alcohol Clin Exp Res 28:662&#x02013;666 <pub-id pub-id-type="pmid">15100619</pub-id></citation></ref><ref id="CR34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shai</surname><given-names>I</given-names></name><name><surname>Wainstein</surname><given-names>J</given-names></name><name><surname>Harman-Boehm</surname><given-names>I</given-names></name><etal/></person-group><article-title>Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>3011</fpage><lpage>3016</lpage><pub-id pub-id-type="doi">10.2337/dc07-1103</pub-id></citation><citation citation-type="display-unstructured">Shai I, Wainstein J, Harman-Boehm I et al (2007) Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial. Diabetes Care 30:3011&#x02013;3016 <pub-id pub-id-type="pmid">17848609</pub-id></citation></ref><ref id="CR35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bantle</surname><given-names>AE</given-names></name><name><surname>Thomas</surname><given-names>W</given-names></name><name><surname>Bantle</surname><given-names>JP</given-names></name></person-group><article-title>Metabolic effects of alcohol in the form of wine in persons with type 2 diabetes mellitus</article-title><source>Metabolism</source><year>2008</year><volume>57</volume><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2007.09.007</pub-id></citation><citation citation-type="display-unstructured">Bantle AE, Thomas W, Bantle JP (2008) Metabolic effects of alcohol in the form of wine in persons with type 2 diabetes mellitus. Metabolism 57:241&#x02013;245 <pub-id pub-id-type="pmid">18191055</pub-id></citation></ref><ref id="CR36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name></person-group><article-title>Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease</article-title><source>Diabetes Care</source><year>1991</year><volume>14</volume><fpage>173</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.2337/diacare.14.3.173</pub-id></citation><citation citation-type="display-unstructured">DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173&#x02013;194 <pub-id pub-id-type="pmid">2044434</pub-id></citation></ref><ref id="CR37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Shlomo</surname><given-names>YB</given-names></name><etal/></person-group><article-title>Alcohol dehydrogenase type 1C (ADH1C) variants, alcohol consumption traits, HDL-cholesterol and risk of coronary heart disease in women and men: British Women&#x02019;s Heart and Health Study and Caerphilly cohorts</article-title><source>Atherosclerosis</source><year>2008</year><volume>196</volume><fpage>871</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2007.02.002</pub-id></citation><citation citation-type="display-unstructured">Ebrahim S, Lawlor DA, Shlomo YB et al (2008) Alcohol dehydrogenase type 1C (ADH1C) variants, alcohol consumption traits, HDL-cholesterol and risk of coronary heart disease in women and men: British Women&#x02019;s Heart and Health Study and Caerphilly cohorts. Atherosclerosis 196:871&#x02013;878 <pub-id pub-id-type="pmid">17379229</pub-id></citation></ref><ref id="CR38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>PA</given-names></name><name><surname>Gregorio</surname><given-names>GB</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Rassouli</surname><given-names>N</given-names></name><name><surname>Ranganathan</surname><given-names>G</given-names></name></person-group><article-title>Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-&#x003b1; expression</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>1779</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.7.1779</pub-id></citation><citation citation-type="display-unstructured">Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-&#x003b1; expression. Diabetes 52:1779&#x02013;1785 <pub-id pub-id-type="pmid">12829646</pub-id></citation></ref><ref id="CR39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engeli</surname><given-names>S</given-names></name><name><surname>Feldpausch</surname><given-names>M</given-names></name><name><surname>Gorzelniak</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association between adiponectin and mediators of inflammation in obese women</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>942</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.4.942</pub-id></citation><citation citation-type="display-unstructured">Engeli S, Feldpausch M, Gorzelniak K et al (2003) Association between adiponectin and mediators of inflammation in obese women. Diabetes 52:942&#x02013;947 <pub-id pub-id-type="pmid">12663465</pub-id></citation></ref><ref id="CR40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guebre-Egziabher</surname><given-names>F</given-names></name><name><surname>Drai</surname><given-names>J</given-names></name><name><surname>Fouque</surname><given-names>D</given-names></name></person-group><article-title>Adiponectin and chronic kidney disease</article-title><source>J Ren Nutr</source><year>2007</year><volume>17</volume><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1053/j.jrn.2006.10.003</pub-id></citation><citation citation-type="display-unstructured">Guebre-Egziabher F, Drai J, Fouque D (2007) Adiponectin and chronic kidney disease. J Ren Nutr 17:9&#x02013;12 <pub-id pub-id-type="pmid">17198925</pub-id></citation></ref><ref id="CR41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rasouli</surname><given-names>N</given-names></name><name><surname>Yao-Borengasser</surname><given-names>A</given-names></name><name><surname>Miles</surname><given-names>LM</given-names></name><name><surname>Elbein</surname><given-names>SC</given-names></name><name><surname>Kern</surname><given-names>PA</given-names></name></person-group><article-title>Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression</article-title><source>Am J Physiol Endocrinol Metab</source><year>2006</year><volume>290</volume><fpage>E42</fpage><lpage>E46</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00240.2005</pub-id></citation><citation citation-type="display-unstructured">Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA (2006) Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 290:E42&#x02013;E46 <pub-id pub-id-type="pmid">16118250</pub-id></citation></ref><ref id="CR42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lam</surname><given-names>KS</given-names></name><name><surname>Yau</surname><given-names>MH</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group><article-title>Post-translational modifications of adiponectin: mechanisms and functional implications</article-title><source>Biochem J</source><year>2008</year><volume>409</volume><fpage>623</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1042/BJ20071492</pub-id></citation><citation citation-type="display-unstructured">Wang Y, Lam KS, Yau MH, Xu A (2008) Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 409:623&#x02013;633 <pub-id pub-id-type="pmid">18177270</pub-id></citation></ref><ref id="CR43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Horikoshi</surname><given-names>M</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1357</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.2337/dc05-1801</pub-id></citation><citation citation-type="display-unstructured">Hara K, Horikoshi M, Yamauchi T et al (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357&#x02013;1362 <pub-id pub-id-type="pmid">16732021</pub-id></citation></ref><ref id="CR44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bobbert</surname><given-names>T</given-names></name><name><surname>Rochlitz</surname><given-names>H</given-names></name><name><surname>Wegewitz</surname><given-names>U</given-names></name><etal/></person-group><article-title>Changes of adiponectin oligomer composition by moderate weight reduction</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>2712</fpage><lpage>2719</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.9.2712</pub-id></citation><citation citation-type="display-unstructured">Bobbert T, Rochlitz H, Wegewitz U et al (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712&#x02013;2719 <pub-id pub-id-type="pmid">16123361</pub-id></citation></ref><ref id="CR45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bluher</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>AM</given-names></name><name><surname>Kelesidis</surname><given-names>T</given-names></name><etal/></person-group><article-title>Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>280</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.2337/dc06-1362</pub-id></citation><citation citation-type="display-unstructured">Bluher M, Brennan AM, Kelesidis T et al (2007) Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 30:280&#x02013;285 <pub-id pub-id-type="pmid">17259495</pub-id></citation></ref><ref id="CR46"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name></person-group><article-title>Adiponectin as an anti-inflammatory factor</article-title><source>Clin Chim Acta</source><year>2007</year><volume>380</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2007.01.026</pub-id></citation><citation citation-type="display-unstructured">Ouchi N, Walsh K (2007) Adiponectin as an anti-inflammatory factor. Clin Chim Acta 380:24&#x02013;30 <pub-id pub-id-type="pmid">17343838</pub-id></citation></ref><ref id="CR47"><label>47.</label><citation citation-type="other">Hung J, McQuillan BM, Thompson PL, Beilby JP (2008) Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) DOI dx.doi.org/10.1038/sj.ijo.0803793</citation></ref><ref id="CR48"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Inflammation, stress, and diabetes</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>1111</fpage><lpage>1119</lpage></citation><citation citation-type="display-unstructured">Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111&#x02013;1119 <pub-id pub-id-type="pmid">15864338</pub-id></citation></ref><ref id="CR49"><label>49.</label><citation citation-type="other">American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund (WCRF) American Institute for Cancer Research (AICR), Washington DC</citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>EtG</term><def><p>ethyl glucuronide</p></def></def-item><def-item><term>HMW</term><def><p>high molecular weight</p></def></def-item><def-item><term>HOMA-IR</term><def><p>homeostasis model assessment of insulin resistance</p></def></def-item><def-item><term>PAI-1</term><def><p>plasminogen activator inhibitor 1</p></def></def-item><def-item><term>PPAR</term><def><p>peroxisome proliferator-activated receptor</p></def></def-item></def-list></glossary></back></article> 